Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Living Cell Technologies ( (AU:1AI) ) has provided an announcement.
Algorae Pharmaceuticals has made significant strides in the past year by advancing its AI-enabled drug discovery platform and securing a commercial partnership with Sakar Healthcare Limited to launch oncology generics in Australia and New Zealand. This move marks the company’s first step toward establishing a branded presence in the region. The company is also progressing in its therapeutic pipeline with promising preclinical results for its dementia and cardiovascular disease candidates. Financially, Algorae has improved its net loss and increased revenue, demonstrating financial discipline and setting the stage for stronger future revenues. The company is poised for further growth with the upcoming launch of AlgoraeOS Version 2.0 and ongoing validation testing with the Peter MacCallum Cancer Centre.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is a company operating in the pharmaceutical industry, focusing on AI-enabled drug discovery. The company is advancing its proprietary AI drug discovery platform, AlgoraeOS, and is working on developing oncology generics and therapeutic candidates in neurology and cardiovascular diseases. Algorae is expanding its market presence in Australia and New Zealand through strategic partnerships and licensing agreements.
Average Trading Volume: 10,231,180
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$13.5M
See more data about 1AI stock on TipRanks’ Stock Analysis page.